Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Undifferentiated Arthritis

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03466814

IM101-635

Details and patient eligibility

About

Observational study of abatacept in the treatment of JIA in Japan.

Enrollment: 82 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All JIA participants who initiate treatment with Orencia in accordance with the prescribing information

Exclusion criteria

• Participants receiving Orencia for an off-label indication

Other protocol defined inclusion/exclusion criteria could apply

Trial design

82 participants in 1 patient group

JIA participants

Treatment:

Other: Non-Interventional